Back to announcement
20250522_SDPC_Laporan Informasi dan Fakta Material_31888413_lamp1.pdf
Other Text extracted SDPCSource file signed link, expires in 15 minutes
Extracted text 2
Page 1 OCR 0.928
PT MILLENNIUM PHARMACON INTERNATIONAL Tbk No. : 342/MPI/DIR/V/2025 Jakarta, 22 Mei 2025 Lampiran : - Perihal 1 Laporan Informasi atau Fakta Material Yth. Kepala Eksekutif Pengawas Pasar Modal Otoritas Jasa Keuangan Gedung Soemitro Djojohadikusumo Jalan Lapangan Banteng Timur 2-4 Jakarta 10710 Sehubungan dengan Peraturan Otoritas Jasa Keuangan (OJK) no: 31/POJK.04/2015 tanggal 16 Desember 2015 tentang Keterbukaan Informasi atas Fakta Material oleh Emiten atau Perusahaan Publik dan Surat Keputusan Direksi PT Bursa Efek Indonesia No. Kep-00066/BEI/09-2022 tanggal 30 September 2022 perihal Perubahan Peraturan Nomor I-E tentang Kewajiban Penyampaian Informasi, dengan ini kami menyampaikan Laporan Informasi atau Fakta Material sebagai berikut : In reference to Financial Services Authority Regulation No.: 31/POJK.04/2015 dated 16 December 2015 regarding Disclosure of Material Information or Facts by Issuer or Public Company and Decission of the Chairman of the Indonesian Stock Exchange Number Kep-00060/BE1/09-2022 dated 30 September 2022 on Amendment of Regulations No. I-E on Obligation to Information Disclosure, we hereby disclose the information and Material Facts as follow: Nama Emiten atau Perusahaan Publik//ssuer: PT Millennium Pharmacon International Tbk (“Perseroan”) Bidang Usaha/Scope of Business : Distribusi produk farmasi, suplemen makanan dan alat kesehatan Telepon/Phone 1 (021) 2708 5961, (021) 2708 5964 Faksimili/Facsimile 1 (021) 2708 5958 Alamat surat elektronik/e-mail 1 Investor.relation@mpi-pharmaniaga.co.id 1 | Tanggal kejadian Date Event 22 Mei 2025 May 22”, 2025 2 | Jenis Informasi atau Fakta Material Type of Information or Material Facts Perpanjangan dan penambahan fasilitas | The renewal and additional loan facilit» pinjaman 3 | Uraian Informasi atau Fakta Material Description of Information or Material Facts a) Pihak-pihak yang melakukan perjanjian: | 4) Parties to the agreement : Company and Perseroan dan PT Bank Central Asia Tbk: PT Bank Central Asia Tbk, b) Bank telah menyetujui perpanjangan dan | b) The Bank has approved a renewal and penambahan fasilitas pinjaman sebesar additional IDR30 billion in loan facilities, Rp30 Miliar sehingga total plafond raising the company's total loan limit to pinjaman menjadi Rp335 Miliar kepada IDR335 billion, Perseroan : Crown Bungur Arteri 2-4th Floors Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia Phone : #6221 27085961
Page 2 OCR 0.907
MPI : PT MILLENNIUM PHARMACON INTERNATIONAL Tbk c) Jenis Fasilitas : Kredit Multi Fasilitas (KMF) : d) Jangka waktu fasilitas adalah 1 (satu) tahun, €) Type of Facility : Mulry-Facility Credit d) The facility tenor is 1 (one) year. 4 | Dampak kejadian, informasi atau fakta material tersebut terhadap kegiatan Operasional, hukum, kondisi keuangan, atau kelangsungan usaha Emiten atau Perusahaan Publik Fasilitas Pinjaman akan menunjang kegiatan usaha perseroan. Impact for such information or material fact towards operational activity, legal, financial condition or business continuity of Issuer or Public Company This loan will support Company's business activities. 5 | Keterangan lain-lain Other Information Tidak ada None Hormat kami, PT Millennium Pharmacon International Tbk PT. (AMACON INTERNATIONAL Tok NamB: Mollamad Fazly bin Hassan Jabatan: Direktur Tembusan: PT Bursa Efek Indonesia u.p. Yth. Direksi Crown Bungur Arteri 2-4th Floors Jl. Sultan Iskandar Muda No. 18, Jakarta 12240, Indonesia Phone : #6221 27085961
Names mentioned 6 people and organisations named in the text · linked when the evidence is strong
unresolved
org
Financial Services Authority
p.1
unresolved
person
NamB: Mollamad Fazly bin Hassan
· Jabatan: Direktur
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.